DocStoX is a free AI-powered research platform for Indian equity markets, covering 5,700+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (5,700+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 94 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Jenburkt Pharmaceutical L (JENBURPH) share price today?

Jenburkt Pharmaceutical L (JENBURPH) is trading at ₹925.6 on the BSE, up 1.04% on the day. Source: DocStoX.

What is the PE ratio of Jenburkt Pharmaceutical L?

Jenburkt Pharmaceutical L has a price-to-earnings (PE) ratio of 11.8 in the Healthcare sector.

What is the market capitalisation of Jenburkt Pharmaceutical L?

Jenburkt Pharmaceutical L has a market capitalisation of approximately ₹406 crore.

Is Jenburkt Pharmaceutical L a profitable company?

Jenburkt Pharmaceutical L generates a return on equity of 17.6% with a net profit margin of 20.6%. That is a reasonable return on shareholder capital.

What is the 52-week high and low of JENBURPH?

Jenburkt Pharmaceutical L (JENBURPH) has traded between ₹864 and ₹1,073.9 over the past 52 weeks, against a current price of ₹925.6.

Does Jenburkt Pharmaceutical L pay a dividend?

Yes. Jenburkt Pharmaceutical L currently offers a dividend yield of 2.02%. Dividend payments depend on the board's declaration each year.

Jenburkt Pharmaceutical L

₹925.60▲ +9.55 (+1.04%)

JENBURPH·BSE·Healthcare

Market Cap

406.44 Cr

PE Ratio

11.76

Volume

141

Day High - Low

925.60 - 910.20

52W High-Low

1073.90 - 864.00

₹925.60▲ +9.55 (+1.04%)

Market Cap406.44 Cr

PE Ratio11.76

Volume141

Day High - Low925.60 - 910.20

52W High-Low1073.90 - 864.00

Jenburkt Pharmaceutical L (JENBURPH): company summary

The company's annual revenue rose 11.2% to ₹169 crore, while annual net profit increased 8.4% to ₹35 crore.

Jenburkt Pharmaceutical L (JENBURPH) is a micro-cap Healthcare company valued at ₹406 crore operating in Pharmaceuticals on the NSE and BSE.

Recent price move: Jenburkt Pharmaceutical L last traded at ₹925.6, modestly up 1.04% on the day.
Recent developments: On 2026-08-28, the company announced a dividend of ₹20.70 per share, with the ex-date set for that day. In the latest quarter, net profit dropped significantly, indicating a challenge in maintaining profitability despite stable revenue.
Financial performance: The company's annual revenue rose 11.2% to ₹169 crore, while annual net profit increased 8.4% to ₹35 crore. However, the latest quarter showed a decline in net profit, falling 24.4% to ₹6 crore compared to the same quarter a year earlier, despite revenue remaining flat at ₹36 crore.
Valuation multiples: The stock trades at 11.8 times earnings, a discount to the Healthcare median of 32.0, 2.33 times book value. It yields 2.0%.
Things to watch: The stock is 14.0% below its 52-week high. Net profit margin fell 0.6 percentage points to 20.6%. Domestic institutional holding decreased by 0.09 points in the quarter.
Where it stands: The company has shown consistent revenue and profit growth over the past five years, with annual revenue up 9.1% and net profit up 16.8%. However, the latest quarter's net profit fell 24.4% compared to the same quarter a year earlier, highlighting a recent challenge in profitability.

Summarised by DocStoX's model on 2026-10-18 from company filings, exchange data and news. This is a factual summary, not a rating or a recommendation. Informational only, not investment advice. Consult a SEBI-registered adviser before investing.

DocStoX Score

6.7/10

Fair

Fair Value

ROE

17.63%

Strong

P/E

11.76x

Cheap

Debt / Equity

0.00

Low

Industry

Healthcare

Pharmaceuticals

Overall View

Mixed

Price performance

Day₹910.20

₹925.60

52W₹864.00

₹1074

DocStoX take

Supported by risk (8.6) and quality (7.6), but held back by momentum (2.0). Risk looks strong at 8.6, but that is offset by momentum at 2.0. We are calling it Mixed rather than resolving the conflict for you.

DocStoX score

Low confidence

6.7

/10

Fair

Quality

Excellent

ROE 17.6%

Valuation

Fair

P/E 11.8×

Growth

Steady

Revenue +9.1% 5Y CAGR

Risk

Low risk

D/E 0.00

Momentum

Weak

29% of 52-week range

DocStoX research

Our verdict

Fairly Valued

Fair value not available

Current price

₹926

Upside / Downside

—

Implied CAGR

—

Priced in by the market

Uncertainty

—

Est. confidence

At a glance

Market Cap

₹406 Cr

52W High / Low

₹1074 / ₹864

Dividend Yield

2.02%

Promoter Holding

46.62%

EPS (TTM)

₹78.71

Book Value

₹446.47

Key highlights

Low leverage — D/E 0.00
Profitable in all of the last 5 years
Undemanding at 12× earnings
Momentum is weak (2.0/10)
Small ₹406 cr company — thinner liquidity

4 Positives2 Watchouts

Growth

Financials

Shareholding

Technicals

Peers

News

Forecasts

About the company

More data

Filings, corporate actions and ownership detail — opened on demand.

More Healthcare stocks · Pharmaceuticals

Explore JENBURKT PHARMACEUTICAL L’s valuation

Free deep-dive tools · no sign-up

Fair ValueOur fair-value estimate, upside, and Bear/Base/Bull scenarios.Intrinsic ValueGraham & earnings-power intrinsic value with margin of safety.DCFDiscounted cash flow — free cash flow, growth, value per share.ValuationP/E, P/B, earnings yield and the full multiples picture.Financial RatiosProfitability, leverage and efficiency ratios at a glance.PeersHow it stacks up against its closest listed competitors.

JENBURKT PHARMACEUTICAL L peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

SUN PHARMACEUTICAL IND L DIVI S LABORATORIES LTD TORRENT PHARMACEUTICALS L LAURUS LABS LIMITED ZYDUS LIFESCIENCES LTD APOLLO HOSPITALS ENTER. L CIPLA LTD DR. REDDY S LABORATORIES AUROBINDO PHARMA LTD MANKIND PHARMA LIMITED LUPIN LIMITED MANIPAL HEALTH ENTERPRI L

Compare JENBURKT PHARMACEUTICAL L with peers

JENBURKT PHARMACEUTICAL L vs SUN PHARMACEUTICAL IND L JENBURKT PHARMACEUTICAL L vs DIVI S LABORATORIES LTD JENBURKT PHARMACEUTICAL L vs TORRENT PHARMACEUTICALS L JENBURKT PHARMACEUTICAL L vs LAURUS LABS LIMITED JENBURKT PHARMACEUTICAL L vs ZYDUS LIFESCIENCES LTD JENBURKT PHARMACEUTICAL L vs APOLLO HOSPITALS ENTER. L

Related tools & concepts

Value JENBURKT PHARMACEUTICAL L with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Explore further

JENBURPH newsLatest coverage & filings Open screenerFilter the whole market